140 related articles for article (PubMed ID: 30422316)
1. Increasing therapy-related myeloid neoplasms in multiple myeloma.
Fernández-Caballero M; Salmerón D; Dolores Chirlaque M; Chen-Liang TH; Hurtado AM; García Malo MD; Ortuño FJ; Roldán V; Vicente V; Jerez A; De Arriba F
Eur J Clin Invest; 2019 Feb; 49(2):e13050. PubMed ID: 30422316
[TBL] [Abstract][Full Text] [Related]
2. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Pemmaraju N; Shah D; Kantarjian H; Orlowski RZ; Nogueras González GM; Baladandayuthapani V; Jain N; Wagner V; Garcia-Manero G; Shah J; Ravandi F; Pierce S; Takahashi K; Daver N; Nazha A; Verstovsek S; Jabbour E; De Lima M; Champlin R; Cortes J; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):110-4. PubMed ID: 25107338
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Mailankody S; Pfeiffer RM; Kristinsson SY; Korde N; Bjorkholm M; Goldin LR; Turesson I; Landgren O
Blood; 2011 Oct; 118(15):4086-92. PubMed ID: 21795746
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
8. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
9. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
Jonsdottir G; Lund SH; Björkholm M; Turesson I; Wahlin A; Mailankody S; Blimark C; Hultcrantz M; Porwit A; Landgren O; Kristinsson SY
Haematologica; 2016 Apr; 101(4):e145-8. PubMed ID: 26681760
[No Abstract] [Full Text] [Related]
10. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
11. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
12. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Gertz MA; Terpos E; Dispenzieri A; Kumar S; Shah RA; Orlowski R; Kastritis E; Dimopoulos MA; Shah J
Leuk Lymphoma; 2015 Jun; 56(6):1723-6. PubMed ID: 25284489
[TBL] [Abstract][Full Text] [Related]
14. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Yamasaki S; Yoshimoto G; Kohno K; Henzan H; Aoki T; Tanimoto K; Sugio Y; Muta T; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Miyamoto T; Akashi K; Iwasaki H;
Int J Hematol; 2019 Jan; 109(1):98-106. PubMed ID: 30251131
[TBL] [Abstract][Full Text] [Related]
15. [Second primary malignancies among patients with myeloma-related-diseases in the KMF database].
Kosugi S; Shibayama H; Nakatani E; Kida T; Ohta K; Kaneko H; Yagi H; Tanaka H; Fuchida S; Nakaya A; Kobayashi M; Kuroda J; Kamitsuji Y; Uoshima N; Adachi Y; Tsudo M; Shimazaki C; Nomura S; Hino M; Matsumura I; Taniwaki M; Kanakura Y; Takaori-Kondo A
Rinsho Ketsueki; 2016 Jul; 57(7):839-47. PubMed ID: 27498726
[TBL] [Abstract][Full Text] [Related]
16. The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation.
Munker R; Shi R; Nair B; Devarakonda S; Cotelingam JD; McLarty J; Mills GM; Glass J
Acta Haematol; 2016; 135(3):146-55. PubMed ID: 26588024
[TBL] [Abstract][Full Text] [Related]
17. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
18. Second primary malignancies and myeloma therapy: fad or fact?
Usmani SZ
Oncotarget; 2012 Sep; 3(9):915-6. PubMed ID: 22989934
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
Duong VH; Holtzman NG; Koka R; Singh ZN; Zou Y; Emadi A; Rapoport AP; Kocoglu MH; Baer MR; Badros AZ
Leuk Lymphoma; 2019 Dec; 60(14):3577-3580. PubMed ID: 31282234
[No Abstract] [Full Text] [Related]
20. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
Haase D; Hanf V; Schulz T
Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
